1832 Asset Management
ASND icon

1832 Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

1832 Asset Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-110,000
Closed -$23.5M – 655
2025
Q4 		$23.5M Hold
110,000
– – 0.02% 283
2025
Q3 		$21.9M Buy
+110,000
New +$20.5M 0.02% 259

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management's ASND Position: Q1 2026 in Review

1832 Asset Management sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 110,000 shares — an estimated $23.5M sold.

1832 Asset Management first reported a position in ASND in Q3 2025 and held it in 2 quarters. The position peaked at $23.5M in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • 1832 Asset Management reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
  • 1832 Asset Management sold 110,000 Ascendis Pharma A/S shares in Q1 2026, an estimated $23.5M.
  • 1832 Asset Management first reported a position in Ascendis Pharma A/S in Q3 2025 and held it in 2 quarters.
  • 1832 Asset Management's Ascendis Pharma A/S position peaked at $23.5M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.